Research ExplorerPublicationsAsymmetric dimethylarginine as an independent risk marker fo...

Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease.

Standard

Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. / Böger, Rainer; Endres, H G; Schwedhelm, Edzard; Darius, H; Atzler, Dorothee; Lüneburg, Nicole; von Stritzky, B; Maas, Renke; Thiem, U; Benndorf, Ralf; Diehm, C.

In: J INTERN MED, Vol. 269, No. 3, 3, 2011, p. 349-361.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Böger, R, Endres, HG, Schwedhelm, E, Darius, H, Atzler, D, Lüneburg, N, von Stritzky, B, Maas, R, Thiem, U, Benndorf, R & Diehm, C 2011, 'Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease.', J INTERN MED, vol. 269, no. 3, 3, pp. 349-361. <http://www.ncbi.nlm.nih.gov/pubmed/21175900?dopt=Citation>

APA

Böger, R., Endres, H. G., Schwedhelm, E., Darius, H., Atzler, D., Lüneburg, N., von Stritzky, B., Maas, R., Thiem, U., Benndorf, R., & Diehm, C. (2011). Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J INTERN MED, 269(3), 349-361. [3]. http://www.ncbi.nlm.nih.gov/pubmed/21175900?dopt=Citation

Vancouver

Böger R, Endres HG, Schwedhelm E, Darius H, Atzler D, Lüneburg N et al. Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J INTERN MED. 2011;269(3):349-361. 3.

Bibtex

@article{0cb9866cc91d40ef9e67829b58a74024,
title = "Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease.",
abstract = "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis causing endothelial dysfunction, an early sign of atherogenesis. Symmetric dimethylarginine (SDMA) does not inhibit NO synthases. Peripheral arterial disease (PAD) is a systemic indication of atherosclerosis.",
author = "Rainer B{\"o}ger and Endres, {H G} and Edzard Schwedhelm and H Darius and Dorothee Atzler and Nicole L{\"u}neburg and {von Stritzky}, B and Renke Maas and U Thiem and Ralf Benndorf and C Diehm",
year = "2011",
language = "English",
volume = "269",
pages = "349--361",
journal = "J INTERN MED",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease.

AU - Böger, Rainer

AU - Endres, H G

AU - Schwedhelm, Edzard

AU - Darius, H

AU - Atzler, Dorothee

AU - Lüneburg, Nicole

AU - von Stritzky, B

AU - Maas, Renke

AU - Thiem, U

AU - Benndorf, Ralf

AU - Diehm, C

PY - 2011

Y1 - 2011

N2 - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis causing endothelial dysfunction, an early sign of atherogenesis. Symmetric dimethylarginine (SDMA) does not inhibit NO synthases. Peripheral arterial disease (PAD) is a systemic indication of atherosclerosis.

AB - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis causing endothelial dysfunction, an early sign of atherogenesis. Symmetric dimethylarginine (SDMA) does not inhibit NO synthases. Peripheral arterial disease (PAD) is a systemic indication of atherosclerosis.

M3 - SCORING: Journal article

VL - 269

SP - 349

EP - 361

JO - J INTERN MED

JF - J INTERN MED

SN - 0954-6820

IS - 3

M1 - 3

ER -